Zhitong Finance App News, Zhiyun Health (09955) announced that the group enjoys sales rights for its own products and Tang JingThe dapagliflozin tablet marketing conference was held on March 9, 2024, marking that the product has entered the marketing and sales stage after officially obtaining the drug registration certificate (Sinopharm license H20234636) issued by the China Drug Administration on December 13, 2023.
According to reports, dapagliflozin tablets are the only essential drug in the sodium-glucose co-transporter 2 (SGLT-2) inhibitor class. Dagliptin was approved to enter the Chinese market in 2017, included in China's medical insurance category B catalogue in 2019, and annual sales in China reached approximately RMB 7 billion in 2023. As an SGLT-2 inhibitor, dapagliflozin tablets are first-line medication for improving blood sugar control in adult patients with type 2 diabetes. Multiple studies have shown that dapagliflozin tablets can comprehensively manage multiple risk factors for heart and kidney disease, and have certain effects in reducing glycated hemoglobin, weight loss, uric acid, reducing the ratio of urinary albumin to creatinine, and reducing systolic blood pressure. The breakthrough direction of this SGLT-2 inhibitor is weight loss, prevention and treatment of cardiovascular disease and kidney disease, and has considerable cross-border value.
With Tang JingDapagliflozin tablets broke through the original patent restrictions, and Chinese generic pharmaceutical products as dapagliflozin tablets were marketed early in accordance with the law. With Tang JingWith the launch of dagliflozin tablets, the group will use its extensive hospital network and offline pharmacy network to market, promote and sell this product, efficiently develop a broad market for the product in a digital manner, give full play to the effects of this product on improving the quality of life of patients with chronic diseases, and enhance the accessibility of high-quality drugs to patients.
The board of directors believes that with Tang JingThe launch of dapagliflozin tablets is a strong confirmation of the company's transition from patient to industrial model, and is expected to have a positive effect on the company's financial performance and long-term development.